SYSTIMMUNE Antibody-Drug Conjugate Patent with Acidic Stabilization Junction
Summary
The USPTO granted Patent US12605458B2 to SYSTIMMUNE, Inc. on April 21, 2026, covering an antibody-drug conjugate with a hydrophilic acidic stabilization junction designed to maintain desired pharmacokinetic properties at higher drug loading. The patent, filed June 15, 2018, contains 18 claims and is classified under multiple therapeutic CPC codes including A61P 35/00 (anti-neoplastic), A61P 29/00 (anti-inflammatory), and A61P 37/02 (immunomodulators).
What changed
The USPTO issued Patent US12605458B2 to SYSTIMMUNE, Inc. for an antibody-drug conjugate featuring a hydrophilic acidic stabilization junction. The innovation allows for higher drug loading per targeted reagent while preserving pharmacokinetic properties and maintaining or improving therapeutic activity. The patent names five inventors and covers the conjugate's structure and therapeutic applications across oncology, inflammation, and immunology indications.
For pharmaceutical and biotechnology companies developing antibody-drug conjugates, this grant establishes exclusive rights for SYSTIMMUNE in the US market for the claimed conjugate architecture. Competitors pursuing similar stabilization junction designs should evaluate potential freedom-to-operate risks. The therapeutic focus areas (A61P 35/00, 29/00, 37/02) indicate the patent's relevance to oncology, anti-inflammatory, and immunomodulatory drug development programs.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibody-drug conjugate having acidic self-stabilization junction
Grant US12605458B2 Kind: B2 Apr 21, 2026
Assignee
SYSTIMMUNE, INC.
Inventors
Yi Zhu, Yiqian Wang, Jie Li, Shi Zhuo, Weili Wan
Abstract
The present invention provides a special drug conjugate having a hydrophilic acidic stabilization junction. Compared with a conjugate having a lower drug loading, due to the introduction of the acidic stabilization junction, the conjugate in the present invention can also have a higher drug loading (that is, each targeted reagent has more hydrophilic drug junctions), keeps a desired PK property and has a same or better activity in a body.
CPC Classifications
A61K 47/6889 A61K 47/545 A61K 47/65 A61K 47/68031 A61K 47/6849 A61K 47/6851 A61K 45/06 A61K 47/6859 A61K 38/07 A61K 47/6803 A61P 35/00 A61P 29/00 A61P 37/02 C07K 16/303
Filing Date
2018-06-15
Application No.
16971219
Claims
18
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.